Agios Pharmaceuticals (AGIO) Enterprise Value (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Enterprise Value of -$737.0 million for Q1 2026, up 13.74% on a QoQ basis from -$854.4 million in Q4 2025, and up 17.5% year-over-year from -$627.3 million in Q1 2025.
Agios Pharmaceuticals (AGIO) Enterprise Value (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Enterprise Value history runs 15 years deep, the most recent figure standing at -$737.0 million for Q1 2026.
- Quarterly Enterprise Value rose 17.5% year-over-year to -$737.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$737.0 million (up 17.5% YoY) and the FY2025 annual result came in at -$854.4 million, up 4.4% from the prior year.
- Enterprise Value was -$737.0 million for Q1 2026 at Agios Pharmaceuticals, up from -$854.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$569.9 million in Q2 2024 and bottomed at -$1.0 billion in Q3 2024.
- A 5-year average of -$797.8 million and a median of -$783.1 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 60.46% — and 2025, when it slumped 64.76%.
- Agios Pharmaceuticals' Enterprise Value stood at -$783.1 million in 2022, then increased by 0.79% to -$776.9 million in 2023, then slipped by 15.03% to -$893.7 million in 2024, then climbed by 4.4% to -$854.4 million in 2025, then increased by 13.74% to -$737.0 million in 2026.
- Business Quant data shows AGIO's Enterprise Value at -$737.0 million in Q1 2026, -$854.4 million in Q4 2025, and -$952.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -737.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -737.04 Mn |
| Dec 31, 2025 | -854.43 Mn |
| Sep 30, 2025 | -952.86 Mn |
| Jun 30, 2025 | -938.94 Mn |
| Mar 31, 2025 | -893.38 Mn |
| Dec 31, 2024 | -893.71 Mn |
| Sep 30, 2024 | -1.00 Bn |
| Jun 30, 2024 | -569.89 Mn |
| Mar 31, 2024 | -597.99 Mn |
| Dec 31, 2023 | -776.93 Mn |
| Sep 30, 2023 | -647.49 Mn |
| Jun 30, 2023 | -702.57 Mn |
| Mar 31, 2023 | -739.20 Mn |
| Dec 31, 2022 | -783.12 Mn |
| Sep 30, 2022 | -727.68 Mn |
| Jun 30, 2022 | -819.31 Mn |
| Mar 31, 2022 | -923.53 Mn |
| Dec 31, 2021 | -1.02 Bn |
| Sep 30, 2021 | -1.27 Bn |
| Jun 30, 2021 | -1.67 Bn |